2024-28230. Notifying the Food and Drug Administration of a Permanent Discontinuance in the Manufacture or an Interruption of the Manufacture of an Infant Formula; Draft Guidance for Industry; Availability; Agency Information Collection Activities; ...  

  • Table 1—Estimated Annual Reporting Burden 1

    Activity; section 424(a)(1) of the FD&C Act Number of respondents Number of responses per respondent Total annual responses Average burden per response Total hours
    Notification of a permanent discontinuance or an interruption of the manufacture of a critical food 8 1 8 2 16
    1  There are no capital costs or operating and maintenance costs associated with this collection of information.

    The estimates in table 1 are based on our experience with similar notification programs. We estimate that each year 5 manufacturers of infant formula will submit notifications in compliance with section 424(a)(1) of the FD&C Act and following recommendations found in the draft guidance. We also estimate that each year 3 manufacturers of medical foods will submit notifications in compliance with section 424(a)(1) of the FD&C Act, for a total of 8 manufacturers of a critical food. We estimate that each manufacturer will submit 1 notification for 8 total annual notifications (8 manufacturers × 1 notification). Each submission will take an estimated 2 hours to complete for an annual reporting burden of 16 hours (8 notifications × 2 hours).

    Table 2—Estimated Annual Recordkeeping Burden 1

    Activity; section 424(b) of the FD&C Act Number of respondents Number of responses per respondent Total annual responses Average burden per response Total hours
    Risk management plan 11 1 11 60 660
    1  There are no capital costs or operating and maintenance costs associated with this collection of information.

Document Information

Published:
12/04/2024
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice of availability.
Document Number:
2024-28230
Dates:
Submit either electronic or written comments on the draft guidance by February 18, 2025 to ensure that we consider your comment on this draft guidance before we begin work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by February 3, 2025.
Pages:
96261-96263 (3 pages)
Docket Numbers:
Docket No. FDA-2024-D-1334
PDF File:
2024-28230.pdf